Johnson & Johnson Shares Fall After COVID-19 Vaccine Stall

February 3, 2018 Fremont / CA / USA - Johnson & Johnson logo in front of one of their office buildings, Fremont, East San Francisco bay area, California.
Sundry Photography / Shutterstock.com

Commitment to Our Readers

GOBankingRates' editorial team is committed to bringing you unbiased reviews and information. We use data-driven methodologies to evaluate financial products and services - our reviews and ratings are not influenced by advertisers. You can read more about our editorial guidelines and our products and services review methodology.

20 Years
Helping You Live Richer

Reviewed
by Experts

Trusted by
Millions of Readers

Johnson & Johnson stock looks to be feeling the nasty side effects of bad company news, dropping 2.3% on Tuesday. The dip follows news reported by STAT on late Monday night that, following an unexplained illness experienced by a participant, the company has paused its late-stage coronavirus vaccine study.

CFO Joseph Wolk expanded on the company statement on CNBC’s “Squawk Box,” stating, “We’re letting safety protocol follow proper procedure here.” He added that the pause in the vaccine study should “reassure the public that every scientific, medical and ethical standard is being applied here.”

Phase three of Johnson & Johnson’s clinical trials, which rolled out in September, comprised 60,000 participants — twice the size of trial studies from fellow vaccine makers Moderna and Pfizer. It’s not clear just how close to the finish line Johnson & Johnson was before progress was halted due to the “adverse event,” as the participant’s illness has been described. There’s also no word on what exactly the person is suffering from.

“We must respect this participant’s privacy,” Johnson & Johnson said in a statement late Monday. “We’re also learning more about this participant’s illness, and it’s important to have all the facts before we share additional information.”

There’s also no word yet on if or when the trial will resume. Just as it remains in question what a future vaccine might cost.

More From GOBankingRates

BEFORE YOU GO

See Today's Best
Banking Offers

Looks like you're using an adblocker

Please disable your adblocker to enjoy the optimal web experience and access the quality content you appreciate from GOBankingRates.

  • AdBlock / uBlock / Brave
    1. Click the ad blocker extension icon to the right of the address bar
    2. Disable on this site
    3. Refresh the page
  • Firefox / Edge / DuckDuckGo
    1. Click on the icon to the left of the address bar
    2. Disable Tracking Protection
    3. Refresh the page
  • Ghostery
    1. Click the blue ghost icon to the right of the address bar
    2. Disable Ad-Blocking, Anti-Tracking, and Never-Consent
    3. Refresh the page